The Nottingham-based company Montague Diagnostics Limited (trading as Montague Healthcare) has merged with the Russian company Mimex Inc to form Mimex Montague Healthcare Limited (MMHL) company registered in England & Wales no 8439352. This will enable the Directors of MMHL (Euan Temple, Chairman; Graham Ewing, CEO; Emir Kamaric, Clinical Director; IG Grakov, Technical Director) to attract the investment which is required to commercialise Virtual Scanning in all world markets.
Virtual Scanning is the first medical technology of its type. It is a cognitive, computer-based, games-like technology which is based upon an original mathematical model of the autonomic nervous system and physiological systems. This is totally unprecedented in contemporary medicine. It is the first technology to link cognition to cellular & molecular biology. It does so because proteins absorb and emit light as they react i.e. the emitted bioluminescence alters our colour perception. The consequences of this technology are both screening and therapeutic i.e. (i) to link deficiencies in our spectrum of colour perception to the onset of pathologies and (ii) to provide colour supplements in the form of a biofeedback light therapy.
The technology has been described in a series of 50 articles which have been published in internationally peer-reviewed medical journals, books and book chapters. Strannik Virtual Scanning and Strannik Light Therapy have been used in Russia since the mid 1990's. The technology was first approved in the Russian Health Services in 2001. Over 500 Russian doctors have been trained to use this technology. It appears able to diagnose the onset of pathologies in a level of sophistication which is unprecedented in modern medicine i.e. (i) earlier than current screening technologies and (ii) at the systemic, organ, cellular and molecular level. Initial evaluation have illustrated that this single technology may be up to 21% more accurate than a wide range of contemporary screening techniques and that the Light Therapy may be up to 93% effective. The technology does so at a price level which has the potential to make immense cost-savings.
There are many precedents for such a technology e.g. (i) colour-based therapies, (ii) flashing light therapies which are currently used to treat dyslexia, migraine and other conditions, (iii) light-based therapies which are used to treat Seasonal Affective Disorder, (iv) the altered colour perception in the diabetic, and which occurs following the absorption of drugs and vaccines e.g. Viagra, etc.
The benefits of this technology are considerable e.g. to enable multiple screening testing in a single cognitive test (a full medical screen), improve the screening of morbidities, treat autonomic dysfunction which is a significant component of most medical conditions, and significantly reduce the cost of diagnosing and treating morbidities.
This technology is well suited for emerging Telemedicine apps such as 'Doctor on Demand' aiming to reduce the need for non-emergency visits. For doctors, the apps are a tool to build a public profile, attract new patients, improve the patient experience, reduce the overall cost of providing healthcare; and for hospitals, they're a means to streamline care for existing patients.
Graham Ewing, CEO Mimex Montague Healthcare Limited
Mimex Montague Healthcare Limited,
Mulberry House, 6 Vine Farm Close,
United Kingdom NG12 3TU
tel: 0044 115 9899618 fax: 0044 115 9899826 mobile: 0044 7885 755847
Company registered in England & Wales no 8439352